1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Enterobacteriaceae Infection Drug Revenue 1.4 Market Analysis by Type 1.4.1 Global Enterobacteriaceae Infection Drug Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Beta-lactams Drugs 1.4.3 Carbapenems Drugs 1.4.4 Fluoroquinolones Drugs 1.4.5 Others 1.5 Market by Application 1.5.1 Global Enterobacteriaceae Infection Drug Market Share by Application: 2020 VS 2026 1.5.2 Hospital Pharmacies 1.5.3 Retail Pharmacies 1.5.4 Online Pharmacies 1.6 Coronavirus Disease 2019 (Covid-19): Enterobacteriaceae Infection Drug Industry Impact 1.6.1 How the Covid-19 is Affecting the Enterobacteriaceae Infection Drug Industry 1.6.1.1 Enterobacteriaceae Infection Drug Business Impact Assessment - Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Enterobacteriaceae Infection Drug Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Enterobacteriaceae Infection Drug Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Global Growth Trends by Regions 2.1 Enterobacteriaceae Infection Drug Market Perspective (2015-2026) 2.2 Enterobacteriaceae Infection Drug Growth Trends by Regions 2.2.1 Enterobacteriaceae Infection Drug Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Enterobacteriaceae Infection Drug Historic Market Share by Regions (2015-2020) 2.2.3 Enterobacteriaceae Infection Drug Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Enterobacteriaceae Infection Drug Market Growth Strategy 2.3.6 Primary Interviews with Key Enterobacteriaceae Infection Drug Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Enterobacteriaceae Infection Drug Players by Market Size 3.1.1 Global Top Enterobacteriaceae Infection Drug Players by Revenue (2015-2020) 3.1.2 Global Enterobacteriaceae Infection Drug Revenue Market Share by Players (2015-2020) 3.1.3 Global Enterobacteriaceae Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Enterobacteriaceae Infection Drug Market Concentration Ratio 3.2.1 Global Enterobacteriaceae Infection Drug Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Enterobacteriaceae Infection Drug Revenue in 2019 3.3 Enterobacteriaceae Infection Drug Key Players Head office and Area Served 3.4 Key Players Enterobacteriaceae Infection Drug Product Solution and Service 3.5 Date of Enter into Enterobacteriaceae Infection Drug Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Enterobacteriaceae Infection Drug Historic Market Size by Type (2015-2020) 4.2 Global Enterobacteriaceae Infection Drug Forecasted Market Size by Type (2021-2026) 5 Enterobacteriaceae Infection Drug Breakdown Data by Application (2015-2026) 5.1 Global Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) 5.2 Global Enterobacteriaceae Infection Drug Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Enterobacteriaceae Infection Drug Market Size (2015-2020) 6.2 Enterobacteriaceae Infection Drug Key Players in North America (2019-2020) 6.3 North America Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) 6.4 North America Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) 7 Europe 7.1 Europe Enterobacteriaceae Infection Drug Market Size (2015-2020) 7.2 Enterobacteriaceae Infection Drug Key Players in Europe (2019-2020) 7.3 Europe Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) 7.4 Europe Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) 8 Asia-Pacific 8.1 Asia-Pacific Enterobacteriaceae Infection Drug Market Size (2015-2020) 8.2 Enterobacteriaceae Infection Drug Key Players in Asia-Pacific (2019-2020) 8.3 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) 8.4 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (2015-2020) (2015-2020) 9 Key Players Profiles 9.1 Genentech 9.1.1 Genentech Company Details 9.1.2 Genentech Business Overview and Its Total Revenue 9.1.3 Genentech Enterobacteriaceae Infection Drug Introduction 9.1.4 Genentech Revenue in Enterobacteriaceae Infection Drug Business (2015-2020)) 9.1.5 Genentech Recent Development 9.2 Nanotherapeutics 9.2.1 Nanotherapeutics Company Details 9.2.2 Nanotherapeutics Business Overview and Its Total Revenue 9.2.3 Nanotherapeutics Enterobacteriaceae Infection Drug Introduction 9.2.4 Nanotherapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.2.5 Nanotherapeutics Recent Development 9.3 Novartis 9.3.1 Novartis Company Details 9.3.2 Novartis Business Overview and Its Total Revenue 9.3.3 Novartis Enterobacteriaceae Infection Drug Introduction 9.3.4 Novartis Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.3.5 Novartis Recent Development 9.4 Pfizer 9.4.1 Pfizer Company Details 9.4.2 Pfizer Business Overview and Its Total Revenue 9.4.3 Pfizer Enterobacteriaceae Infection Drug Introduction 9.4.4 Pfizer Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.4.5 Pfizer Recent Development 9.5 Nymox Pharmaceutical 9.5.1 Nymox Pharmaceutical Company Details 9.5.2 Nymox Pharmaceutical Business Overview and Its Total Revenue 9.5.3 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Introduction 9.5.4 Nymox Pharmaceutical Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.5.5 Nymox Pharmaceutical Recent Development 9.6 Sequoia Sciences 9.6.1 Sequoia Sciences Company Details 9.6.2 Sequoia Sciences Business Overview and Its Total Revenue 9.6.3 Sequoia Sciences Enterobacteriaceae Infection Drug Introduction 9.6.4 Sequoia Sciences Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.6.5 Sequoia Sciences Recent Development 9.7 Phico Therapeutics 9.7.1 Phico Therapeutics Company Details 9.7.2 Phico Therapeutics Business Overview and Its Total Revenue 9.7.3 Phico Therapeutics Enterobacteriaceae Infection Drug Introduction 9.7.4 Phico Therapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.7.5 Phico Therapeutics Recent Development 9.8 Cantab Biopharmaceuticals 9.8.1 Cantab Biopharmaceuticals Company Details 9.8.2 Cantab Biopharmaceuticals Business Overview and Its Total Revenue 9.8.3 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Introduction 9.8.4 Cantab Biopharmaceuticals Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) 9.8.5 Cantab Biopharmaceuticals Recent Development 10 Analyst's Viewpoints/Conclusions 11 Appendix 11.1 Research Methodology 11.1.1 Methodology/Research Approach 11.1.2 Data Source 11.2 Disclaimer 11.3 Author Details

List of Tables Table 1. Enterobacteriaceae Infection Drug Key Market Segments Table 2. Key Players Covered: Ranking by Enterobacteriaceae Infection Drug Revenue Table 3. Ranking of Global Top Enterobacteriaceae Infection Drug Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Enterobacteriaceae Infection Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Beta-lactams Drugs Table 6. Key Players of Carbapenems Drugs Table 7. Key Players of Fluoroquinolones Drugs Table 8. Key Players of Others Table 9. COVID-19 Impact Global Market: (Four Enterobacteriaceae Infection Drug Market Size Forecast Scenarios) Table 10. Opportunities and Trends for Enterobacteriaceae Infection Drug Players in the COVID-19 Landscape Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis Table 12. Key Regions/Countries Measures against Covid-19 Impact Table 13. Proposal for Enterobacteriaceae Infection Drug Players to Combat Covid-19 Impact Table 14. Global Enterobacteriaceae Infection Drug Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 15. Global Enterobacteriaceae Infection Drug Market Size by Regions (US$ Million): 2020 VS 2026 Table 16. Global Enterobacteriaceae Infection Drug Market Size by Regions (2015-2020) (US$ Million) Table 17. Global Enterobacteriaceae Infection Drug Market Share by Regions (2015-2020) Table 18. Global Enterobacteriaceae Infection Drug Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 19. Global Enterobacteriaceae Infection Drug Market Share by Regions (2021-2026) Table 20. Market Top Trends Table 21. Key Drivers: Impact Analysis Table 22. Key Challenges Table 23. Enterobacteriaceae Infection Drug Market Growth Strategy Table 24. Main Points Interviewed from Key Enterobacteriaceae Infection Drug Players Table 25. Global Enterobacteriaceae Infection Drug Revenue by Players (2015-2020) (Million US$) Table 26. Global Enterobacteriaceae Infection Drug Market Share by Players (2015-2020) Table 27. Global Top Enterobacteriaceae Infection Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Enterobacteriaceae Infection Drug as of 2019) Table 28. Global Enterobacteriaceae Infection Drug by Players Market Concentration Ratio (CR5 and HHI) Table 29. Key Players Headquarters and Area Served Table 30. Key Players Enterobacteriaceae Infection Drug Product Solution and Service Table 31. Date of Enter into Enterobacteriaceae Infection Drug Market Table 32. Mergers & Acquisitions, Expansion Plans Table 33. Global Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$) Table 34. Global Enterobacteriaceae Infection Drug Market Size Share by Type (2015-2020) Table 35. Global Enterobacteriaceae Infection Drug Revenue Market Share by Type (2021-2026) Table 36. Global Enterobacteriaceae Infection Drug Market Size Share by Application (2015-2020) Table 37. Global Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$) Table 38. Global Enterobacteriaceae Infection Drug Market Size Share by Application (2021-2026) Table 39. North America Key Players Enterobacteriaceae Infection Drug Revenue (2019-2020) (Million US$) Table 40. North America Key Players Enterobacteriaceae Infection Drug Market Share (2019-2020) Table 41. North America Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$) Table 42. North America Enterobacteriaceae Infection Drug Market Share by Type (2015-2020) Table 43. North America Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$) Table 44. North America Enterobacteriaceae Infection Drug Market Share by Application (2015-2020) Table 45. Europe Key Players Enterobacteriaceae Infection Drug Revenue (2019-2020) (Million US$) Table 46. Europe Key Players Enterobacteriaceae Infection Drug Market Share (2019-2020) Table 47. Europe Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$) Table 48. Europe Enterobacteriaceae Infection Drug Market Share by Type (2015-2020) Table 49. Europe Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$) Table 50. Europe Enterobacteriaceae Infection Drug Market Share by Application (2015-2020) Table 51. Asia-Pacific Key Players Enterobacteriaceae Infection Drug Revenue (2019-2020) (Million US$) Table 52. Asia-Pacific Key Players Enterobacteriaceae Infection Drug Market Share (2019-2020) Table 53. Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Type (2015-2020) (Million US$) Table 54. Asia-Pacific Enterobacteriaceae Infection Drug Market Share by Type (2015-2020) Table 55. Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Application (2015-2020) (Million US$) Table 56. Asia-Pacific Enterobacteriaceae Infection Drug Market Share by Application (2015-2020) Table 57. Genentech Company Details Table 58. Genentech Business Overview Table 59. Genentech Product Table 60. Genentech Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 61. Genentech Recent Development Table 62. Nanotherapeutics Company Details Table 63. Nanotherapeutics Business Overview Table 64. Nanotherapeutics Product Table 65. Nanotherapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 66. Nanotherapeutics Recent Development Table 67. Novartis Company Details Table 68. Novartis Business Overview Table 69. Novartis Product Table 70. Novartis Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 71. Novartis Recent Development Table 72. Pfizer Company Details Table 73. Pfizer Business Overview Table 74. Pfizer Product Table 75. Pfizer Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 76. Pfizer Recent Development Table 77. Nymox Pharmaceutical Company Details Table 78. Nymox Pharmaceutical Business Overview Table 79. Nymox Pharmaceutical Product Table 80. Nymox Pharmaceutical Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 81. Nymox Pharmaceutical Recent Development Table 82. Sequoia Sciences Company Details Table 83. Sequoia Sciences Business Overview Table 84. Sequoia Sciences Product Table 85. Sequoia Sciences Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 86. Sequoia Sciences Recent Development Table 87. Phico Therapeutics Company Details Table 88. Phico Therapeutics Business Overview Table 89. Phico Therapeutics Product Table 90. Phico Therapeutics Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 91. Phico Therapeutics Recent Development Table 92. Cantab Biopharmaceuticals Business Overview Table 93. Cantab Biopharmaceuticals Product Table 94. Cantab Biopharmaceuticals Company Details Table 95. Cantab Biopharmaceuticals Revenue in Enterobacteriaceae Infection Drug Business (2015-2020) (Million US$) Table 96. Cantab Biopharmaceuticals Recent Development Table 97. Research Programs/Design for This Report Table 98. Key Data Information from Secondary Sources Table 99. Key Data Information from Primary Sources List of Figures Figure 1. Global Enterobacteriaceae Infection Drug Market Share by Type: 2020 VS 2026 Figure 2. Beta-lactams Drugs Features Figure 3. Carbapenems Drugs Features Figure 4. Fluoroquinolones Drugs Features Figure 5. Others Features Figure 6. Global Enterobacteriaceae Infection Drug Market Share by Application: 2020 VS 2026 Figure 7. Hospital Pharmacies Case Studies Figure 8. Retail Pharmacies Case Studies Figure 9. Online Pharmacies Case Studies Figure 10. Enterobacteriaceae Infection Drug Report Years Considered Figure 11. Global Enterobacteriaceae Infection Drug Market Size YoY Growth 2015-2026 (US$ Million) Figure 12. Global Enterobacteriaceae Infection Drug Market Share by Regions: 2020 VS 2026 Figure 13. Global Enterobacteriaceae Infection Drug Market Share by Regions (2021-2026) Figure 14. Porter's Five Forces Analysis Figure 15. Global Enterobacteriaceae Infection Drug Market Share by Players in 2019 Figure 16. Global Top Enterobacteriaceae Infection Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Enterobacteriaceae Infection Drug as of 2019 Figure 17. The Top 10 and 5 Players Market Share by Enterobacteriaceae Infection Drug Revenue in 2019 Figure 18. North America Enterobacteriaceae Infection Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Europe Enterobacteriaceae Infection Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Asia-Pacific Enterobacteriaceae Infection Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Genentech Total Revenue (US$ Million): 2019 Compared with 2018 Figure 22. Genentech Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 23. Nanotherapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 24. Nanotherapeutics Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 25. Novartis Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Novartis Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 27. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Pfizer Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 29. Nymox Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Nymox Pharmaceutical Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 31. Sequoia Sciences Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Sequoia Sciences Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 33. Phico Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Phico Therapeutics Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 35. Cantab Biopharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Cantab Biopharmaceuticals Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2015-2020) Figure 37. Bottom-up and Top-down Approaches for This Report Figure 38. Data Triangulation Figure 39. Key Executives Interviewed

Genentech Nanotherapeutics Novartis Pfizer Nymox Pharmaceutical Sequoia Sciences Phico Therapeutics Cantab Biopharmaceuticals